The decision hands Moderna its second-only product approval to date after its Covid jab, which has generated more than $40bn in revenue. Its blockbuster Covid shot propelled the Boston-based ...
Synopsys VC Verification IP (VIP) for Fibre Channel is designed to thoroughly verify Fibre Channel designs using both random and directed simulation. The Fibre Channel VIP provides full protocol ...
Synthesia's new technology is impressive but raises big questions about a world where we increasingly can’t tell what’s real. The FDA is poised to approve the notorious party drug as a therapy. Here’s ...
Moderna Inc. gained US approval for its RSV vaccine in older adults, giving the biotech company a second product as it seeks to move beyond its reliance on the fading market for Covid-19 shots ...
Moderna Inc.’s respiratory syncytial virus vaccine for older adults received U.S. regulatory approval, the company said Friday, marking the first time a messenger RNA vaccine has been approved ...
The approval is a big moment for Moderna, which previously only had just one product, its COVID shot. Like rival Pfizer, Moderna’s stock price has plunged as the world moves on from the pandemic.
Moderna's RSV shot is the first messenger RNA-based (mRNA) vaccine not for COVID-19 to be approved in the United States. It will be sold under the brand name mRESVIA The company has said mRNA ...
A researcher at the Moderna headquarters in Cambridge, Mass. (Adam Glanzman/Bloomberg News) Moderna, the biotech that rose to fame for making one of the world’s first Covid-19 vaccines ...
The facility, which will be the drugmaker's first end-to-end ADC production site, will be supported by the Singapore Economic Development Board. The company did not provide details on the possible ...
Covid-19 cases are relatively low right ... The company said it could get the shot to US warehouses by August. Pfizer and Moderna’s mRNA vaccines can be developed more quickly, and those ...